Clinical Epigenetics

Table 2 Clinical features of TCGA patients based on EDARADD expression and methylation

From: Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer

TCGA DNA methylation	Bottom 0.25	Top 0.75	Pvalue
Patients, no.	97	290
Age, median (range)	62 (47–75)	62 (44–78)	0.5339^a
Gleason Grade Group, no. (%)
GG1	1 (1%)	26 (9%)	< 0.0001^b
GG2	18 (19%)	96 (33%)
GG3	18 (19%)	63 (21%)
GG4	16 (16%)	36 (12%)
GG5	44 (45%)	69 (24%)
Clinical features, no. (%)
Pathologic T stage 2	24 of 96 (25%)	115 of 286 (40%)	0.0072^c
Pathologic T stage 3+	72 (75%)	171 (60%)	0.0072^c
Lymph node involvement	33 of 91 (36%)	36 of 240 (13%)	< 0.0001^d
Patient follow-up
Relapse, no of events	44	26
Log rank test^e			0.0095
Cox model^e			0.0167
TCGA RNA levels	Top 0.25	Bottom 0.75	Pvalue
Patients, no.	95	285
Age, median (range)	62 (46–78)	62 (44–77)	0.7623^a
Gleason Grade Group, no. (%)
GG1	1 (1%)	26 (9%)	< 0.0001^b
GG2	20 (24%)	94 (33%)
GG3	20 (24%)	61 (21%)
GG4	13 (15%)	36 (13%)
GG5	41 (48%)	68 (24%)
Clinical features, no. (%)
Pathologic T stage 2	16 of 94 (17%)	120 of 281 (43%)	< 0.0001^c
Pathologic T stage 3+	78 (83%)	161 (57%)	< 0.0001^c
Lymph node involvement	28 of 90 (31%)	34 of 223 (15%)	0.0026^d
Patient follow up
Relapse, no of events	42	27
Log rank test^f			0.0054
Cox model^f			0.0005

Sample numbers are based on the availability of clinical, methylation (387 samples) and expression (380 samples) data. Numbers in italics denote sample numbers where data was not available for some cases
^aUnpaired T test with Welch’s correction
^bChi-squared test for trend
^cThe Fisher exact test comparing the proportion of patients with T2 versus T3 disease
^dChi-squared test
^eLog rank HR = 0.48 (0.28–0.84), Cox model HR = 0.10 (0.012–0.66)
^fLog rank HR 1.96 (1.13–3.39), Cox model HR = 1.41 (1.16–1.72)

Back to article page

ISSN: 1868-7083

Contact us

Submission enquiries: avalyn.villar@springernature.com
General enquiries: info@biomedcentral.com